Prescient Therapeutics
Manufacturing · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
100 Albert Rd L 4, South Melbourne, Vict...Phone Number
+61 396927222Website
www.ptxtherapeutics.comRevenue
<$5 MillionStock Symbol
PTXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Prescient Therapeutics
Prescient Therapeutics is a clinical stage biotechnology company focused on developing targeted therapies and cell therapies for cancer treatment. Their key products include PTX-100, a first-in-class targeted therapy for T cell lymphomas, and the CellPryme and OmniCAR platforms designed to enhance CAR-T therapy efficacy. The company collaborates with leading institutions such as Yale and Oxford University to advance its innovative pipeline. Prescient aims to improve outcomes for cancer patients, particularly those with unmet medical needs.Explore more
Prescient Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
UB
Director, Clinical Affairs & Operations
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Prescient Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check out if Prescient Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Prescient Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Prescient Therapeutics has new funding data
Product Launch: Get notified when Prescient Therapeutics launches new products
Prescient Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Prescient Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Prescient Therapeutics
Check if Prescient Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Prescient Therapeutics
Find 2 more new buyers
Compare Similar Companies to Prescient Therapeutics
Compare insights from companies similar to Prescient Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Prescient Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Prescient Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Prescient Therapeutics.
Prescient Therapeutics financials insights
Gather financial insights about Prescient Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Share Placement
$7M
Prescient Therapeutics Tech Stack
A closer look at the technologies used by Prescient Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Left Company
Executive Move
Executive Moves, Left Company
Funding
Funding
Prescient Therapeutics News & Media
Prescient Therapeutics Limited (PSTTF) Discusses Clinical Progress of PTX-100 in Cancer Trials and Regulatory Milestones Transcript
Prescient Therapeutics Limited (OTC:PSTTF) Discusses Clinical Progress of PTX-100 in Cancer Trials and Regulatory Milestones October 19, 2025 8:01 PM...Prescient Therapeutics Limited (PSTTF) Shareholder/Analyst Call Transcript
Prescient Therapeutics Limited (OTC:PSTTF) Shareholder/Analyst Call October 13, 2025 8:01 PM EDTCompany ParticipantsJames CampbellJames McDonnell - Chief...Prescient secures investor support to advance PTX-100 in cancer trials - Biotech Dispatch
Prescient Therapeutics (ASX:PTX) has secured fresh backing from investors, completing a $3 million capital raise to support the clinical development of its targeted cancer therapy PTX-100.Prescient Therapeutics Announces New Office Location Amidst Strategic Growth - TipRanks
The latest update is out from Prescient Therapeutics Limited ( ($AU:PTX) ). Prescient Therapeutics Limited has announced a change in its registered office and princ...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Prescient Therapeutics
Sign Up For FreeTo access detailed company insights
Prescient Therapeutics is a clinical stage biotechnology company focused on developing targeted therapies and cell therapies for cancer treatment. Their key products include PTX-100, a first-in-class targeted therapy for T cell lymphomas, and the CellPryme and OmniCAR platforms designed to enhance CAR-T therapy efficacy. The company collaborates wi... Read More
